Loading stock data…
Silo Pharma, Inc. (SILO)
$2.28-0.01 (-0.44%)
After Hours$2.40+0.12 (+5.26%)· Last close Sep 8
Silo Pharma, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Silo Pharma, Inc. in the Healthcare sector is trading at $2.28 with a market capitalization of $4M. The stock is currently near its 52-week low of $2.21, remaining 58.0% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 11 is oversold, raising the odds of a near-term bounce. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 11) — potential for technical mean-reversion
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $18,026 | $18,026 | $18,025 | $18,025 |
| Gross Profit | $0↑ | -$2,662 | -$2,663 | -$2,662↓ | $16,566 |
| Operating Income | -$928,949↑ | -$1.59M↓ | -$786,524↑ | -$1.15M↑ | -$1.25M |
| Net Income | -$832,829↑ | -$1.65M↓ | -$881,530↑ | -$1.11M↑ | -$1.20M |
Peer Comparison
JNJUNHPFE
Fundamentals
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.00M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.75
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-91.52%
Volume
Today's trading volume
13,777
Recent News
Is Silo Pharma, Inc. (SILO) Stock an AI Opportunity After NVIDIA Partnership Boosts QwikAgents Platform?
We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. Silo Pharma, Inc. (NASDAQ:SILO) is one of the best psychedelic stocks on our list. SILO reported on July 7 that its wholly owned subsidiary, QwikAgents, joined the NVIDIA Developer Program to support the advancement of its artificial intelligence agent integration […]
Silo Pharma’s QwikAgents Joins AMD AI Developer Program to Advance AI Agent Platform
Silo Pharma (NASDAQ:SMPL) announced that its wholly owned subsidiary, QwikAgents, has joined AMD’s AI Developer Program, giving the company access to AI development resources intended to support the expansion of its enterprise and consumer AI agent platform. Key Investor TakeawaysSilo Pharma (NASDAQ:SMPL) said QwikAgents has been accepted into the AMD AI Developer Program.
Silo Pharma Shares Slide After Announcing Up to $11.7 Million Private Placement (SILO)
Silo Pharma Inc. (NASDAQ:SILO) shares dropped 22% on Friday after the company announced an at-the-market private placement that could raise up to $11.
CCC Intelligent Solutions, Circle rise premarket; Silo Pharma, Fermi America fall
Investing.com - U.S. stock index futures edged lower on Friday as investors consolidated gains following Wall Street’s sharp relief rally, with easing crude oil prices and signs of a possible diplomatic breakthrough between Washington and Tehran helping stabilize broader market sentiment.
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector SNDL Reported “Particularly Challenging” First Quarter 2026 Financial and Operational Results Vireo Growth Accelerated Expansion with FLUENT Acquisition, Cementing its Florida Ambitions Aurora Cannabis Expanded Global Medical Portfolio with New International Product Launches Key Takeaways; Psychedelic Sector Silo Pharma Sees Momentum as U.S. Accelerates Psychedelic PTSD Treatments Helus Pharma Expanded Veteran […]